Aaron D Levine

List of Publications by Year
in descending order

26	683	623188 14	610482 24
papers	citations	h-index	g-index

26	26	26	684
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tracking the rise of stem cell tourism. Regenerative Medicine, 2010, 5, 27-33.	0.8	114
2	Challenges in the translation and commercialization of cell therapies. BMC Biotechnology, 2015, 15, 70.	1.7	90
3	Self-Regulation, Compensation, and the Ethical Recruitment of Oocyte Donors. Hastings Center Report, 2010, 40, 25-36.	0.7	78
4	The Roles and Responsibilities of Physicians in Patients' Decisions about Unproven Stem Cell Therapies. Journal of Law, Medicine and Ethics, 2012, 40, 122-134.	0.4	53
5	Revisiting the Warnock rule. Nature Biotechnology, 2017, 35, 1029-1042.	9.4	47
6	Assessing the use of assisted reproductive technology in the United States by nonâ€“United States residents. Fertility and Sterility, 2017, 108, 815-821.	0.5	36
7	Policy Uncertainty and the Conduct of Stem Cell Research. Cell Stem Cell, 2011, 8, 132-135.	5.2	35
8	Identifying Under- and Overperforming Countries in Research Related to Human Embryonic Stem Cells. Cell Stem Cell, 2008, 2, 521-524.	5.2	34
9	Research policy and the mobility of US stem cell scientists. Nature Biotechnology, 2006, 24, 865-866.	9.4	22
10	Insights from Patients' Blogs and the Need for Systematic Data on Stem Cell Tourism. American Journal of Bioethics, 2010, 10, 28-29.	0.5	20
11	Tracking and assessing the rise of state-funded stem cell research. Nature Biotechnology, 2010, 28, 1246-1248.	9.4	18
12	Trends in the geographic distribution of human embryonic stem-cell research. Politics and the Life Sciences, 2004, 23, 40-45.	0.5	17
13	Assessing State Stem Cell Programs in the United States: How Has State Funding Affected Publication Trends?. Cell Stem Cell, 2015, 16, 115-118.	5.2	17
14	The Oversight and Practice of Oocyte Donation in the United States, United Kingdom and Canada. HEC Forum, 2011, 23, 15-30.	0.6	15
15	Risk Disclosure and the Recruitment of Oocyte Donors: Are Advertisers Telling the Full Story?. Journal of Law, Medicine and Ethics, 2014, 42, 232-243.	0.4	14
16	Part 6: The role of communication in better understanding unproven cellular therapies. Cytotherapy, 2016, 18, 143-148.	0.3	14
17	Compliance with donor age recommendations in oocyte donor recruitment advertisements in the USA. Reproductive BioMedicine Online, 2013, 26, 400-405.	1.1	12
18	Policy Considerations for States Supporting Stem Cell Research: Evidence from a Survey of Stem Cell Scientists. Public Administration Review, 2008, 68, 681-694.	2.9	11

#	Article	IF	Citations
19	Medical crowdfunding to access CAR T-cell therapy. Lancet Oncology, The, 2019, 20, 1062-1064.	5.1	11
20	Science, ethics and communication remain essential for the success of cell-based therapies. Brain Circulation, 2016, 2, 146.	0.7	7
21	Assessing workforce needs for the emerging CAR-T cell therapy industry. Nature Biotechnology, 2022, 40, 275-278.	9.4	7
22	Science policy and the geographic preferences of stem cell scientists: understanding the appeal of China and Singapore. New Genetics and Society, 2010, 29, 187-208.	0.7	6
23	Navigating Bioethical Waters: Two Pilot Projects in Problem-Based Learning for Future Bioscience and Biotechnology Professionals. Science and Engineering Ethics, 2016, 22, 1649-1667.	1.7	4
24	State performance in pluripotent and adult stem cell research, 2009â€“2016. Regenerative Medicine, 2018, 13, 309-320.	0.8	1
25	The Troubling History of Regulating Reproduction. Public Administration Review, 2010, 70, 330-332.	2.9	0
26	National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT). , 2022, , 627-654.		0